Explore the words cloud of the LUMABS project. It provides you a very rough idea of what is the project "LUMABS" about.
The following table provides information about the project.
TECHNISCHE UNIVERSITEIT EINDHOVEN
|Coordinator Country||Netherlands [NL]|
|Total cost||149˙750 €|
|EC max contribution||149˙750 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2017-06-01 to 2018-11-30|
Take a look of project's partnership.
|1||TECHNISCHE UNIVERSITEIT EINDHOVEN||NL (EINDHOVEN)||coordinator||149˙750.00|
Therapeutic antibodies represent an important class of newly introduced drugs and have been particularly successful in cancer therapy and the treatment of inflammatory diseases. The clearance rates of therapeutic antibodies are known to differ per individual and correlate with survival rates. Being able to define a personalized dose per patient based on continuous monitoring of therapeutic antibody levels would therefore be beneficial both for the individual patient and for the hospital’s budget. Our group recently developed a new platform of bioluminescent sensor proteins for antibody detection that allow antibody detection directly in blood plasma using the camera of a smart phone as the sole piece of equipment.
The goal of this ERC Proof-of-Concept is to establish LUMABS as a unique, low cost, and easily accessible point-of-care technology for monitoring therapeutic antibodies.
To enable clinical and commercial translation a product portfolio will be established that includes the development and validation of a prototype point-of-care assay for the therapeutic antibody Cetuximab. To establish LUMABS as a broadly applicable platform technology, we will use recently developed epitope screening technology to develop specific LUMABS sensors targeting Infliximab and biosimilar antibodies that are used to treat inflammatory conditions such as Crohns’ disease and rheumatoid arthritis. Based on an in-depth market analysis and the feedback we receive from external stakeholders on the performance of our technology, a realistic strategy will be developed for further translation and commercialization. During the project we will continuously assess opportunities for new patent applications. Our IP strategy will be guided by the outcome of our market examination and analysis of the most interesting business opportunities.
|year||authors and title||journal||last update|
Keisuke Tenda, Benice vanâ€…Gerven, Remco Arts, Yuki Hiruta, Maarten Merkx, Daniel Citterio
Paper-Based Antibody Detection Devices Using Bioluminescent BRET-Switching Sensor Proteins
published pages: 15369-15373, ISSN: 1433-7851, DOI: 10.1002/anie.201808070
|Angewandte Chemie International Edition 57/47||2019-05-16|
Martijn van Rosmalen, Yan Ni, Daan F. M. Vervoort, Remco Arts, Susann K. J. Ludwig, Maarten Merkx
Dual-Color Bioluminescent Sensor Proteins for Therapeutic Drug Monitoring of Antitumor Antibodies
published pages: 3592-3599, ISSN: 0003-2700, DOI: 10.1021/acs.analchem.8b00041
|Analytical Chemistry 90/5||2019-05-16|
Yan Ni, Remco Arts, Maarten Merkx
Ratiometric Bioluminescent Sensor Proteins Based on Intramolecular Split Luciferase Complementation
published pages: 20-25, ISSN: 2379-3694, DOI: 10.1021/acssensors.8b01381
|ACS Sensors 4/1||2019-05-16|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LUMABS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "LUMABS" are provided by the European Opendata Portal: CORDIS opendata.